Atlas Venture

Be Biopharma, Inc. is focused on developing innovative therapeutics derived from engineered B-cells to address various diseases, including cancer, autoimmune disorders, and infectious diseases. Founded in 2020 and based in Cambridge, Massachusetts, the company aims to overcome significant challenges associated with traditional cell and gene therapies, such as the limitations of dosing, unpredictable reactions in patients, and the necessity of pre-treatment chemotherapy. By leveraging precision genome editing, Be Biopharma creates durable and effective cell therapies that can be administered without toxic conditioning, thereby improving treatment options for conditions like Hemophilia B and enhancing overall patient outcomes.

Trace Neuroscience is a biopharmaceutical company dedicated to advancing genetic medicine for patients with neurodegenerative diseases. It specializes in developing targeted antisense oligonucleotide therapies, with its lead product aimed at restoring UNC13A protein function in individuals with Amyotrophic Lateral Sclerosis (ALS) caused by TDP-43 mislocalization. This therapy corrects UNC13A mRNA splicing, potentially improving muscle function and extending survival for these patients.

Be Biopharma, Inc. is focused on developing innovative therapeutics derived from engineered B-cells to address various diseases, including cancer, autoimmune disorders, and infectious diseases. Founded in 2020 and based in Cambridge, Massachusetts, the company aims to overcome significant challenges associated with traditional cell and gene therapies, such as the limitations of dosing, unpredictable reactions in patients, and the necessity of pre-treatment chemotherapy. By leveraging precision genome editing, Be Biopharma creates durable and effective cell therapies that can be administered without toxic conditioning, thereby improving treatment options for conditions like Hemophilia B and enhancing overall patient outcomes.

Judo Bio is a biotechnology company focused on developing precision therapeutics that target specific cell populations to treat genetic diseases. Utilizing an innovative receptor targeting approach, Judo Bio is building a pipeline of therapies designed to benefit patients suffering from both common and rare conditions. Currently, the company is operating in stealth mode, indicating a focus on research and development without public visibility.

Triveni Bio is a biotechnology company specializing in the development of novel antibody therapies for immunological and inflammatory disorders. The company employs a genetics-driven precision medicine approach to identify patients most likely to respond to its treatments, aiming to accelerate drug development and improve the effectiveness and safety of therapies.

Kailera Therapeutics is a biotechnology company focused on developing innovative treatments for obesity and associated conditions. It specializes in injectable and oral GLP-1 (Glucagon-like peptide-1) therapies, aiming to provide patients with transformative health solutions.

PHINXT Robotics specializes in automating warehouse operations through its innovative mobile robotics platform. This platform allows warehouses of all sizes to deploy autonomous robots without requiring specialized expertise. PHINXT Robotics provides a unified system that facilitates real-time coordination and incorporates cloud-edge computing and distributed intelligence. Their services include goods-to-person systems, material handling, and parcel sorting, which collectively enhance operational performance for clients. By simplifying the integration of robotics into warehouse workflows, PHINXT Robotics aims to streamline processes and improve efficiency in logistics and supply chain management.

GRO Biosciences is focused on developing advanced protein therapeutics by utilizing innovative technologies in computational protein design and synthetic biology. The company has created several genomically recoded strains of bacteria that enable the incorporation of non-standard amino acids into proteins. This approach enhances the potency, stability, and targeted delivery of these therapeutics. GRO Biosciences aims to apply its technology to improve treatments for a range of conditions, including diabetes, growth disorders, and autoimmunity, thereby addressing significant unmet medical needs.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative treatments for severe hematologic disorders. Founded in 2017, the company specializes in human genetics-based therapeutics that aim to improve red blood cell production in patients suffering from various hematologic diseases. Disc Medicine's pipeline includes therapeutic candidates targeting critical pathways involved in red blood cell biology, such as heme biosynthesis and iron homeostasis. Notable programs include bitopertin, which is being developed for conditions like erythropoietic porphyrias and Diamond-Blackfan anemia. Through its research and development efforts, Disc Medicine seeks to transform the lives of patients affected by these challenging disorders.

Pheon Therapeutics is a London-based company established in 2022, specializing in the development of Antibody-Drug Conjugates (ADCs) aimed at addressing a variety of difficult-to-treat cancers. The company focuses on creating next-generation ADCs, with its lead program targeting a novel antigen that is significantly expressed in solid tumors across multiple hard-to-treat cancer types. By enhancing the therapeutic options available to healthcare providers, Pheon Therapeutics aims to provide effective treatment alternatives for patients whose cancers do not respond to existing therapies.

Korro Bio Inc., established in 2018 and headquartered in Cambridge, Massachusetts, specializes in developing nucleic acid-based therapeutics targeting specific sequences in genetic code to treat rare diseases. The company's proprietary platform enables efficient and selective RNA editing, leveraging natural processes common to all multicellular organisms. Korro Bio aims to advance this technology to effect changes in protein structure and function across multiple tissues, expanding the reach of genetic medicines with additional precision and tunability by editing RNA instead of DNA.

Diagonal Therapeutics is a biotechnology company specializing in the discovery and development of agonist antibodies. Its innovative platform integrates proprietary computational and experimental methods to overcome historical challenges in agonist antibody drug development, enabling the delivery of therapies for conditions such as hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension.

Q32 Bio Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for severe autoimmune and inflammatory diseases. Established in 2017, the company aims to address immune system dysregulation, providing treatment options for conditions that currently have limited or inadequate therapies. Q32 Bio's pipeline includes ADX-914, a human anti-IL-7R antibody designed to re-regulate adaptive immune function, and ADX-097, which demonstrates effective distribution to affected tissues and robust efficacy. With a team of experienced scientists and industry professionals, Q32 Bio is dedicated to restoring healthy immune balance through novel biologic therapies that target critical pathways in both the innate and adaptive immune systems.

Sionna Therapeutics was formed in late 2019, leveraging 10 years of large pharma scientific investment and expertise. Our experienced scientific team has been on a mission to fully normalize CFTR function. In the three decades since the discovery of the genetic defects that cause cystic fibrosis (CF), researchers have made remarkable advances for patients. Yet the ultimate goal of CF drug development – to fully normalize the function of CFTR, the key protein leading to the pathology of CF – has remained out of reach.

Comanche Biopharma is a biopharmaceutical company focused on developing an investigational small interfering RNA (siRNA) medicine aimed at treating preterm preeclampsia. The company is committed to ensuring that all women and their babies have access to safe and effective therapies for life-threatening complications during pregnancy. Comanche Biopharma's mission emphasizes the importance of evidence-based and affordable solutions, enabling women to receive cost-effective treatments that address the root causes of preeclampsia.

Remix Therapeutics Inc. is a biotechnology company focused on the research and development of innovative small-molecule therapies that target RNA processing to address various diseases. Established in 2018 and based in Cambridge, Massachusetts, the company employs its proprietary biology platform to identify and prioritize therapeutic targets within RNA processing. Through its REMseq platform, Remix Therapeutics validates potential drug targets and optimizes chemical compounds for therapeutic use. The company's approach aims to reprogram RNA processing to control gene expression, thereby correcting, enhancing, or eliminating problematic gene messages. This enables healthcare providers to tackle the underlying causes of diseases, offering novel solutions to previously undruggable conditions.

Judo Bio is a biotechnology company focused on developing precision therapeutics that target specific cell populations to treat genetic diseases. Utilizing an innovative receptor targeting approach, Judo Bio is building a pipeline of therapies designed to benefit patients suffering from both common and rare conditions. Currently, the company is operating in stealth mode, indicating a focus on research and development without public visibility.

Triveni Bio is a biotechnology company specializing in the development of novel antibody therapies for immunological and inflammatory disorders. The company employs a genetics-driven precision medicine approach to identify patients most likely to respond to its treatments, aiming to accelerate drug development and improve the effectiveness and safety of therapies.

Aiolos Bio is a biotechnology company specializing in the development of therapies for respiratory diseases and immune conditions. Its primary focus is on advancing AIO-001, a monoclonal antibody therapy for moderate-to-severe asthma, designed for dosing every 6 months. The company, founded by industry veterans, aims to address unmet treatment needs and improve patient outcomes by providing more efficacious and less burdensome therapies.

Nvelop Therapeutics is engaged in the development of advanced genetic medicines aimed at addressing severe genetic diseases. The company specializes in creating programmable delivery systems that enhance in vivo gene editing and facilitate the delivery of therapeutic cargo. By integrating epigenetic editing technologies with innovative delivery methods, Nvelop Therapeutics targets unmet medical needs, particularly in therapeutically relevant cells and tissues. Their focus on novel gene editing delivery technologies enables medical professionals to effectively deliver a range of therapeutic payloads, thereby improving treatment options for patients suffering from these challenging conditions.

Nimbus Therapeutics, based in Cambridge, Massachusetts, is a biotechnology company focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. The company utilizes advanced computational technologies to create selective and potent small-molecule therapeutics. Among its notable projects is the Nimbus Apollo program, which features the lead candidate NDI-010976, an allosteric inhibitor targeting Acetyl-CoA Carboxylase (ACC). This compound is being developed for the treatment of non-alcoholic steatohepatitis (NASH) and has potential applications in hepatocellular carcinoma (HCC) and other diseases. NDI-010976 received Fast Track designation from the U.S. Food and Drug Administration in 2016, highlighting its significance in the clinical development pipeline. Nimbus Therapeutics has formed strategic partnerships to enhance its research and development capabilities, reinforcing its commitment to advancing treatment options for complex health challenges.

K36 Therapeutics is engaged in the development of small molecule therapeutics aimed at treating cancer. The company focuses on translating epigenetic modulation of oncogenic pathways into effective therapies, utilizing technology to create orally bioavailable small molecules and selective inhibitors. This innovative approach enables healthcare professionals to enhance treatment options for cancer patients, addressing the complexities of oncogenic pathways and improving therapeutic outcomes.

AAVantgarde Bio is a biotechnology company focused on developing gene therapies specifically for inherited retinal disorders. The company utilizes proprietary Adeno-Associated Viral (AAV) vector platforms to overcome the limitations associated with the cargo capacity of traditional AAV vectors. This innovative approach allows for the delivery of large genes to both ocular and non-ocular tissues, enhancing the potential for effective gene therapy solutions. By addressing these challenges, AAVantgarde Bio aims to improve treatment outcomes for patients suffering from these genetic conditions.

Right-Hand Cybersecurity specializes in enhancing organizational security by addressing human factors that contribute to data breaches, which are often linked to employee errors. The company offers an AI-powered cyber and policy awareness platform that analyzes employee behavior in real-time. This platform generates user behavior analytics and provides tailored micro-learning and training nudges, empowering employees to recognize and mitigate risky actions. By personalizing and automating awareness programs, Right-Hand Cybersecurity helps enterprises reduce human risk, foster a strong cyber culture, and ensure compliance with relevant standards.

Pheon Therapeutics is a London-based company established in 2022, specializing in the development of Antibody-Drug Conjugates (ADCs) aimed at addressing a variety of difficult-to-treat cancers. The company focuses on creating next-generation ADCs, with its lead program targeting a novel antigen that is significantly expressed in solid tumors across multiple hard-to-treat cancer types. By enhancing the therapeutic options available to healthcare providers, Pheon Therapeutics aims to provide effective treatment alternatives for patients whose cancers do not respond to existing therapies.

Nimbus Therapeutics, based in Cambridge, Massachusetts, is a biotechnology company focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. The company utilizes advanced computational technologies to create selective and potent small-molecule therapeutics. Among its notable projects is the Nimbus Apollo program, which features the lead candidate NDI-010976, an allosteric inhibitor targeting Acetyl-CoA Carboxylase (ACC). This compound is being developed for the treatment of non-alcoholic steatohepatitis (NASH) and has potential applications in hepatocellular carcinoma (HCC) and other diseases. NDI-010976 received Fast Track designation from the U.S. Food and Drug Administration in 2016, highlighting its significance in the clinical development pipeline. Nimbus Therapeutics has formed strategic partnerships to enhance its research and development capabilities, reinforcing its commitment to advancing treatment options for complex health challenges.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative treatments for severe hematologic disorders. Founded in 2017, the company specializes in human genetics-based therapeutics that aim to improve red blood cell production in patients suffering from various hematologic diseases. Disc Medicine's pipeline includes therapeutic candidates targeting critical pathways involved in red blood cell biology, such as heme biosynthesis and iron homeostasis. Notable programs include bitopertin, which is being developed for conditions like erythropoietic porphyrias and Diamond-Blackfan anemia. Through its research and development efforts, Disc Medicine seeks to transform the lives of patients affected by these challenging disorders.

Remix Therapeutics Inc. is a biotechnology company focused on the research and development of innovative small-molecule therapies that target RNA processing to address various diseases. Established in 2018 and based in Cambridge, Massachusetts, the company employs its proprietary biology platform to identify and prioritize therapeutic targets within RNA processing. Through its REMseq platform, Remix Therapeutics validates potential drug targets and optimizes chemical compounds for therapeutic use. The company's approach aims to reprogram RNA processing to control gene expression, thereby correcting, enhancing, or eliminating problematic gene messages. This enables healthcare providers to tackle the underlying causes of diseases, offering novel solutions to previously undruggable conditions.

Sionna Therapeutics was formed in late 2019, leveraging 10 years of large pharma scientific investment and expertise. Our experienced scientific team has been on a mission to fully normalize CFTR function. In the three decades since the discovery of the genetic defects that cause cystic fibrosis (CF), researchers have made remarkable advances for patients. Yet the ultimate goal of CF drug development – to fully normalize the function of CFTR, the key protein leading to the pathology of CF – has remained out of reach.

Be Biopharma, Inc. is focused on developing innovative therapeutics derived from engineered B-cells to address various diseases, including cancer, autoimmune disorders, and infectious diseases. Founded in 2020 and based in Cambridge, Massachusetts, the company aims to overcome significant challenges associated with traditional cell and gene therapies, such as the limitations of dosing, unpredictable reactions in patients, and the necessity of pre-treatment chemotherapy. By leveraging precision genome editing, Be Biopharma creates durable and effective cell therapies that can be administered without toxic conditioning, thereby improving treatment options for conditions like Hemophilia B and enhancing overall patient outcomes.

Triana Biomedicines is focused on discovering and developing molecular glues, a novel therapeutic approach aimed at regulating challenging disease targets. The company employs a sophisticated drug discovery engine that combines high-resolution structural insights, advanced in silico tools, and custom chemical libraries. This platform is designed to stabilize existing protein interactions or create new ones, thereby influencing the functionality of disease targets. Triana has successfully validated its technology and is currently advancing multiple research programs across various disease areas, positioning itself to contribute significantly to therapeutic innovation.

Arkuda Therapeutics is a biotechnology company based in Cambridge, Massachusetts, founded in 2018. The company focuses on developing innovative medicines for patients suffering from neurological diseases, particularly targeting neurodegenerative conditions. Arkuda leverages insights into progranulin and lysosomal biology to create therapies aimed at addressing progranulin deficiency and lysosomal dysfunction, specifically in genetically-defined frontotemporal dementia related to mutations in the GRN gene. Its lead compounds are designed to improve cellular health in the brain, with the goal of delaying disease progression and the onset of symptoms.

K36 Therapeutics is engaged in the development of small molecule therapeutics aimed at treating cancer. The company focuses on translating epigenetic modulation of oncogenic pathways into effective therapies, utilizing technology to create orally bioavailable small molecules and selective inhibitors. This innovative approach enables healthcare professionals to enhance treatment options for cancer patients, addressing the complexities of oncogenic pathways and improving therapeutic outcomes.

Curie Therapeutics is a fully integrated, next-generation radiopharmaceuticals company focused on pioneering a new class of targeted radiopharmaceuticals that are both safe and effective. Curie's radiopharmaceuticals are composed of rationally designed conjugates against carefully selected biological targets, to deliver alpha and beta-emitting radionuclide payloads.

HotSpot Therapeutics is a biotechnology startup based in Boston, Massachusetts, established in 2017. The company specializes in the development of allosteric therapies that target regulatory sites on proteins. Its innovative therapeutic platform is designed to identify hotspots and locate pathway treatments for cancer, metabolic disorders, and rare diseases. By leveraging a comprehensive database of hotspot structures and utilizing data science, HotSpot Therapeutics employs a multidisciplinary approach to drug discovery. This approach aims to enhance the effectiveness of treatments and improve patient outcomes across a range of conditions.

Matchpoint Therapeutics is a biotechnology company focused on developing precision covalent medicines aimed at transforming the treatment of immune diseases and other serious conditions. Utilizing its proprietary Advanced Covalent Exploration (ACE) platform, the company combines advanced chemoproteomics, machine learning, and the evolution of covalent chemistry libraries to enhance drug discovery. This innovative approach allows for a deeper exploration of the proteome, enabling the identification and targeting of new binding sites on disease-causing proteins. Matchpoint is building an emerging pipeline of novel covalent medicines, with an initial emphasis on immunology.

Rectify Pharmaceuticals is focused on creating disease-modifying precision therapies aimed at addressing the root causes of serious genetic diseases. The company specializes in developing positive functional modulators (PFMs) that restore the function of ABC transporters, which are critical for cellular processes. By targeting these underlying mechanisms, Rectify aims to provide innovative treatment solutions that improve the health outcomes of patients suffering from various genetic conditions. Their research and development efforts encompass multiple therapeutic areas, reflecting a commitment to advancing precision medicine in the field of genetic disorders.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative treatments for severe hematologic disorders. Founded in 2017, the company specializes in human genetics-based therapeutics that aim to improve red blood cell production in patients suffering from various hematologic diseases. Disc Medicine's pipeline includes therapeutic candidates targeting critical pathways involved in red blood cell biology, such as heme biosynthesis and iron homeostasis. Notable programs include bitopertin, which is being developed for conditions like erythropoietic porphyrias and Diamond-Blackfan anemia. Through its research and development efforts, Disc Medicine seeks to transform the lives of patients affected by these challenging disorders.

Versanis Bio is focused on discovering and developing medicines that target medical conditions commonly found in older adults. The company is advancing Bimagrumab, a human monoclonal antibody that inhibits activin type II receptors, blocking the action of ligands such as activin A and myostatin. Previous studies conducted by Novartis involved over 1,500 participants and demonstrated that Bimagrumab consistently induced significant fat loss while preserving lean mass. Additionally, the treatment has shown improvements in HbA1c levels and other cardiometabolic parameters, offering a promising option for overweight and obese adults aiming to achieve and maintain a healthier body composition.

Nimbus Therapeutics, based in Cambridge, Massachusetts, is a biotechnology company focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. The company utilizes advanced computational technologies to create selective and potent small-molecule therapeutics. Among its notable projects is the Nimbus Apollo program, which features the lead candidate NDI-010976, an allosteric inhibitor targeting Acetyl-CoA Carboxylase (ACC). This compound is being developed for the treatment of non-alcoholic steatohepatitis (NASH) and has potential applications in hepatocellular carcinoma (HCC) and other diseases. NDI-010976 received Fast Track designation from the U.S. Food and Drug Administration in 2016, highlighting its significance in the clinical development pipeline. Nimbus Therapeutics has formed strategic partnerships to enhance its research and development capabilities, reinforcing its commitment to advancing treatment options for complex health challenges.

Vedere Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2019. The company focuses on developing gene therapy products aimed at restoring functional vision for patients who have experienced vision loss due to Inherited Retinal Degenerations (IRDs) and other causes of vision impairment, both genetic and non-genetic. Unlike many ocular gene therapies that primarily slow the progression of vision loss, Vedere Bio seeks to restore lost vision, regardless of the patient's genetic background or stage of their condition. As of September 2020, Vedere Bio operates as a subsidiary of Novartis AG.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies that leverage its proprietary technology to maximize the effectiveness of existing immuno-oncology treatments while minimizing side effects outside the tumor. Its lead product, XTX201, is designed to induce immune activity specifically within tumors, demonstrating improved antitumor efficacy. Xilio Therapeutics aims to deliver significant improvements in patient outcomes by utilizing its platform to create a pipeline of novel therapies, including tumor-activated cytokines, antibodies, and immune cell engagers, all targeted to optimize therapeutic effects within the tumor microenvironment. Founded in 2015 and based in Waltham, Massachusetts, the company was previously known as Akrevia Therapeutics before rebranding in March 2020.

Day One Biopharmaceuticals is a clinical-stage biotechnology company that specializes in developing targeted cancer therapies for patients of all ages, with a particular focus on pediatric patients. Recognizing the advancements in cancer research, the company aims to create treatments that can benefit both children and adults diagnosed with genetically defined cancers. Day One Biopharmaceuticals prioritizes the rapid development of therapies to meet the urgent needs of families facing cancer diagnoses. Their lead product candidate, DAY101, is an oral, highly-selective pan-RAF kinase inhibitor designed to penetrate the brain, addressing a significant treatment gap in pediatric oncology. By licensing and acquiring promising products from research institutions and other companies, Day One Biopharmaceuticals strives to bring effective medicines to market for those impacted by cancer.

Gemini Therapeutics, Inc. is a precision medicine company based in Cambridge, Massachusetts, founded in 2015. The company specializes in developing new therapies for patients experiencing dry age-related macular degeneration (AMD) and related rare genetic diseases. Gemini Therapeutics focuses on genetically defined conditions, creating therapeutic candidates that address molecular abnormalities in patients with significant clinical needs. Their diverse pipeline encompasses monoclonal antibodies, recombinant proteins, and gene therapies, positioning the company to potentially introduce first-in-class therapeutics. The development of these innovative treatment options is supported by collaborations with leading life science investors and academic institutions worldwide, reflecting a commitment to advancing medical care for individuals suffering from these conditions.

Ikena Oncology, Inc. is a biotechnology company focused on discovering and developing biomarker-driven therapies for cancer treatment. It specializes in precision oncology by targeting pathways essential for cancer growth and therapeutic resistance, particularly within the Hippo and RAS signaling networks. The company's portfolio includes several preclinical and discovery-stage programs, such as IK-007, an EP4 receptor antagonist; IK-175, an AHR antagonist; and IK-412, a kynurenine-degrading enzyme. Additionally, Ikena is developing IK-930, an oral small-molecule inhibitor of the TEAD transcription factor involved in the Hippo pathway. Ikena Oncology, originally founded as Kyn Therapeutics in 2016, rebranded in December 2019 and is headquartered in Boston, Massachusetts. The company aims to address significant medical needs in oncology through innovative drug development.

Vigil Neuroscience Inc. is a therapeutics company focused on microglia, the brain's immune sentinel cells, to address both rare and common neurodegenerative diseases. The company aims to restore the vigilance of microglia to improve patient outcomes. Vigil is advancing its lead candidate, a monoclonal antibody TREM2 agonist, through Phase 1 studies and is also developing an orally available small molecule TREM2 agonist, VG-3927, which is positioned to enter Investigational New Drug (IND) application. Additionally, Vigil is conducting the IGNITE trial, a Phase 2 proof-of-concept study that represents the first interventional trial for patients with adult-onset leukodystrophy. By leveraging modern neuroscience and various therapeutic modalities, Vigil seeks to deliver precision therapies that enhance the lives of patients and their families while expanding its pipeline and supporting the understanding of microglia biology as a critical therapeutic target.

Remix Therapeutics Inc. is a biotechnology company focused on the research and development of innovative small-molecule therapies that target RNA processing to address various diseases. Established in 2018 and based in Cambridge, Massachusetts, the company employs its proprietary biology platform to identify and prioritize therapeutic targets within RNA processing. Through its REMseq platform, Remix Therapeutics validates potential drug targets and optimizes chemical compounds for therapeutic use. The company's approach aims to reprogram RNA processing to control gene expression, thereby correcting, enhancing, or eliminating problematic gene messages. This enables healthcare providers to tackle the underlying causes of diseases, offering novel solutions to previously undruggable conditions.

Kinaset Therapeutics is a therapeutics company dedicated to developing innovative drugs aimed at addressing unmet medical needs, particularly in the field of respiratory health. The company focuses on creating novel therapeutics for patients suffering from intractable diseases, including severe asthma. Kinaset Therapeutics is advancing its lead asset, which employs a unique approach to treating severe asthma, thereby offering healthcare providers a less invasive and more cost-effective treatment option. Through its efforts, Kinaset Therapeutics aims to make a significant positive impact on the lives of individuals affected by challenging respiratory conditions.

F-Star Therapeutics is a biopharmaceutical company focused on developing novel bispecific antibody products aimed at improving upon current standards of care, particularly in cancer therapy. The company is uniquely positioned with a strong patent portfolio, enabling it to create and develop Fcab antibody fragments and bispecific antibodies by modifying the constant region of an antibody. F-Star's Modular Antibody Technology allows for rapid discovery and development of bispecific antibodies by adding binding sites to the constant region, facilitating easier production compared to other antibody formats. The company is leveraging this technology to build a pipeline of product candidates. Founded in 2006, F-Star has received significant funding from leading venture capital firms and strategic corporate investors. The company operates out of Cambridge, UK, with over 35 employees dedicated to research and development.

Q32 Bio Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for severe autoimmune and inflammatory diseases. Established in 2017, the company aims to address immune system dysregulation, providing treatment options for conditions that currently have limited or inadequate therapies. Q32 Bio's pipeline includes ADX-914, a human anti-IL-7R antibody designed to re-regulate adaptive immune function, and ADX-097, which demonstrates effective distribution to affected tissues and robust efficacy. With a team of experienced scientists and industry professionals, Q32 Bio is dedicated to restoring healthy immune balance through novel biologic therapies that target critical pathways in both the innate and adaptive immune systems.

Scorpion Therapeutics, Inc. is a biotechnology company based in Boston, Massachusetts, focused on developing next-generation precision oncology technologies for cancer treatment. Founded in 2020, the company specializes in creating targeted small-molecule drugs that interact with validated cancer targets. Its research encompasses therapies aimed at known oncogenes, previously undruggable cancer targets, and novel targets. By integrating technologies across target discovery, medicinal chemistry, and translational medicine, Scorpion Therapeutics aims to advance a comprehensive pipeline of optimized compounds. The company's goal is to expand the reach of precision medicine, enabling healthcare professionals to offer innovative treatments to a broader range of cancer patients.

Be Biopharma, Inc. is focused on developing innovative therapeutics derived from engineered B-cells to address various diseases, including cancer, autoimmune disorders, and infectious diseases. Founded in 2020 and based in Cambridge, Massachusetts, the company aims to overcome significant challenges associated with traditional cell and gene therapies, such as the limitations of dosing, unpredictable reactions in patients, and the necessity of pre-treatment chemotherapy. By leveraging precision genome editing, Be Biopharma creates durable and effective cell therapies that can be administered without toxic conditioning, thereby improving treatment options for conditions like Hemophilia B and enhancing overall patient outcomes.

Korro Bio Inc., established in 2018 and headquartered in Cambridge, Massachusetts, specializes in developing nucleic acid-based therapeutics targeting specific sequences in genetic code to treat rare diseases. The company's proprietary platform enables efficient and selective RNA editing, leveraging natural processes common to all multicellular organisms. Korro Bio aims to advance this technology to effect changes in protein structure and function across multiple tissues, expanding the reach of genetic medicines with additional precision and tunability by editing RNA instead of DNA.

Dyne Therapeutics is a biotechnology company based in Waltham, Massachusetts, dedicated to developing targeted therapies for genetically driven muscle diseases. Founded in 2017, the company focuses on advancing treatments for conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, among others. Utilizing its innovative FORCE platform, Dyne Therapeutics aims to deliver disease-modifying therapies with enhanced precision to skeletal, cardiac, and smooth muscle tissues. The company's lead product candidates, DYNE-101 and DYNE-251, are currently undergoing phase 1/2 clinical trials, reflecting its commitment to addressing the unmet medical needs of patients with serious muscle disorders.

Aerovate Therapeutics is a clinical-stage biotechnology company based in Boston, Massachusetts, dedicated to developing innovative treatments for patients with rare cardiopulmonary diseases. The company's primary focus is on AV-101, a proprietary inhaled dry powder formulation of the drug imatinib, designed specifically for the treatment of pulmonary arterial hypertension (PAH). This formulation enables targeted delivery of the medication directly to affected lung tissues, thereby minimizing systemic side effects commonly associated with traditional treatments. Established in 2018, Aerovate aims to provide meaningful improvements in the lives of those suffering from these serious conditions.

Cogent Biosciences is a biotechnology company dedicated to developing precision therapies for genetically defined diseases, aiming to treat the underlying causes and improve patient lives. The company employs proprietary T-cell engineering technology alongside tumor-targeting antibodies to harness the body's immune system against cancer. One of its key programs, CGT9486, is a selective tyrosine kinase inhibitor designed to inhibit specific mutations in KIT exon 17, which are associated with Systemic Mastocytosis and advanced gastrointestinal stromal tumors (GIST).

Q32 Bio Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for severe autoimmune and inflammatory diseases. Established in 2017, the company aims to address immune system dysregulation, providing treatment options for conditions that currently have limited or inadequate therapies. Q32 Bio's pipeline includes ADX-914, a human anti-IL-7R antibody designed to re-regulate adaptive immune function, and ADX-097, which demonstrates effective distribution to affected tissues and robust efficacy. With a team of experienced scientists and industry professionals, Q32 Bio is dedicated to restoring healthy immune balance through novel biologic therapies that target critical pathways in both the innate and adaptive immune systems.

HotSpot Therapeutics is a biotechnology startup based in Boston, Massachusetts, established in 2017. The company specializes in the development of allosteric therapies that target regulatory sites on proteins. Its innovative therapeutic platform is designed to identify hotspots and locate pathway treatments for cancer, metabolic disorders, and rare diseases. By leveraging a comprehensive database of hotspot structures and utilizing data science, HotSpot Therapeutics employs a multidisciplinary approach to drug discovery. This approach aims to enhance the effectiveness of treatments and improve patient outcomes across a range of conditions.

Day One Biopharmaceuticals is a clinical-stage biotechnology company that specializes in developing targeted cancer therapies for patients of all ages, with a particular focus on pediatric patients. Recognizing the advancements in cancer research, the company aims to create treatments that can benefit both children and adults diagnosed with genetically defined cancers. Day One Biopharmaceuticals prioritizes the rapid development of therapies to meet the urgent needs of families facing cancer diagnoses. Their lead product candidate, DAY101, is an oral, highly-selective pan-RAF kinase inhibitor designed to penetrate the brain, addressing a significant treatment gap in pediatric oncology. By licensing and acquiring promising products from research institutions and other companies, Day One Biopharmaceuticals strives to bring effective medicines to market for those impacted by cancer.

Cadent Therapeutics, Inc. is a precision neuroscience company focused on developing innovative therapies for serious neurological and psychiatric disorders. Founded in 2010 and based in Cambridge, Massachusetts, the company specializes in small molecule therapeutics that target NMDA receptors to address conditions such as depression, schizophrenia, Rett syndrome, and other cognitive and movement disorders. Cadent's approach combines target specificity, patient selection, and drug design to create allosteric modulators that can enhance neuronal firing regularity and restore brain rhythms. By leveraging novel quantitative endpoints, Cadent aims to develop first-in-class medications that improve cognitive and motor functions in patients, ultimately enhancing clinical outcomes for those suffering from various neurological diseases.

Accent Therapeutics, Inc. is a biopharmaceutical company based in Lexington, Massachusetts, focused on developing small molecule therapies for oncology through the innovative field of epitranscriptomics. Founded in 2017, the company explores post-transcriptional chemical modifications of RNA, which play a crucial role in regulating proteins essential for cellular growth and differentiation. By precisely targeting RNA-modifying proteins associated with cancer, Accent Therapeutics aims to translate advanced scientific research into effective treatments for patients, ultimately providing new therapeutic options in the fight against cancer.

Affinia Therapeutics Inc. is focused on developing gene therapies for various diseases, particularly those affecting the muscles and central nervous system. The company specializes in creating adeno-associated virus (AAV) vectors, leveraging advanced techniques in synthetic and systems biology, as well as high-throughput screening and tissue and single-cell resolution. Founded in 2019 and based in Waltham, Massachusetts, Affinia aims to address significant unmet medical needs by providing rationally designed gene therapies with improved properties. The company's innovative approach seeks to offer effective treatments for devastating conditions that currently lack adequate therapeutic options.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies that leverage its proprietary technology to maximize the effectiveness of existing immuno-oncology treatments while minimizing side effects outside the tumor. Its lead product, XTX201, is designed to induce immune activity specifically within tumors, demonstrating improved antitumor efficacy. Xilio Therapeutics aims to deliver significant improvements in patient outcomes by utilizing its platform to create a pipeline of novel therapies, including tumor-activated cytokines, antibodies, and immune cell engagers, all targeted to optimize therapeutic effects within the tumor microenvironment. Founded in 2015 and based in Waltham, Massachusetts, the company was previously known as Akrevia Therapeutics before rebranding in March 2020.

Quench Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing therapies for inflammatory diseases through the exploration of gasdermin biology and innate immunity. The company’s lead compounds specifically target and inhibit Gasdermin D, a protein involved in the processes of pyroptosis and NETosis, which play a crucial role in the release of inflammatory cytokines, alarmins, DNA, and neutrophil extracellular traps (NETs). By addressing these pathways, Quench Bio aims to provide relief for patients suffering from severe inflammatory conditions. Originally founded as Project Pyro, the company changed its name to Quench Bio in June 2018.

Generation Bio is a genetic medicines company based in Cambridge, Massachusetts, that specializes in developing innovative gene therapies for both rare and prevalent diseases. Founded in 2016 and originally named Torus Therapeutics, the company focuses on treating conditions primarily affecting the liver and retina, as well as diseases of skeletal muscle, the central nervous system, and oncology. Generation Bio employs a proprietary non-viral platform that includes a high-capacity DNA construct known as closed-ended DNA (ceDNA) and a cell-targeted lipid nanoparticle delivery system (ctLNP). This platform aims to deliver genetic payloads effectively across various tissues and allows for redosable treatments tailored to individual patient needs. Through its advanced manufacturing processes, Generation Bio seeks to expand access to gene therapies and provide durable solutions for patients with both rare and common diseases.

Chroma Medicine is a genomic medicine company founded in 2021 and based in Cambridge, Massachusetts, specializing in epigenetic editing. The company is pioneering a new class of genomic therapies aimed at revolutionizing the treatment of genetically driven diseases. By utilizing epigenetics, which is the natural mechanism for gene regulation, Chroma Medicine develops programmable epigenetic editors that target specific genes and modulate chromatin conformation. This innovative approach enables healthcare providers to achieve precise control of gene expression, offering a promising therapeutic option for conditions linked to genetic anomalies.

Triplet Therapeutics, Inc. is focused on developing innovative therapies for repeat expansion disorders, which include conditions such as Huntington’s disease, myotonic dystrophy, and spinocerebellar ataxias. Founded in 2018 and based in Cambridge, Massachusetts, the company aims to address these disorders at their source by utilizing a unique approach that involves targeting the DNA Damage Response pathway through a single oligonucleotide. This biotherapeutic technology is designed to provide a comprehensive treatment solution for multiple repeat expansion disorders, enabling healthcare professionals to better manage these complex conditions.

IFM Therapeutics specializes in developing small molecule medicines that target the innate immune system to address complex challenges in treating inflammatory and autoimmune disorders, as well as cancer. The company collaborates with academic partners to leverage expertise in innate immunity alongside experienced drug discovery professionals. Its subsidiary, IFM Due, focuses on discovering and developing antagonists of the cGAS/STING pathway, aiming to treat conditions such as inflammation, neuroinflammation, autoimmunity, and cancer. Additionally, IFM Discovery, a newly established incubator within the company, is engaged in advancing a portfolio of genetically validated targets for next-generation therapies addressing inflammation, neuroinflammation, autoimmunity, and fibrosis. Through these initiatives, IFM Therapeutics seeks to enhance immune response and improve the quality of life for patients facing serious health challenges.

Arkuda Therapeutics is a biotechnology company based in Cambridge, Massachusetts, founded in 2018. The company focuses on developing innovative medicines for patients suffering from neurological diseases, particularly targeting neurodegenerative conditions. Arkuda leverages insights into progranulin and lysosomal biology to create therapies aimed at addressing progranulin deficiency and lysosomal dysfunction, specifically in genetically-defined frontotemporal dementia related to mutations in the GRN gene. Its lead compounds are designed to improve cellular health in the brain, with the goal of delaying disease progression and the onset of symptoms.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative treatments for severe hematologic disorders. Founded in 2017, the company specializes in human genetics-based therapeutics that aim to improve red blood cell production in patients suffering from various hematologic diseases. Disc Medicine's pipeline includes therapeutic candidates targeting critical pathways involved in red blood cell biology, such as heme biosynthesis and iron homeostasis. Notable programs include bitopertin, which is being developed for conditions like erythropoietic porphyrias and Diamond-Blackfan anemia. Through its research and development efforts, Disc Medicine seeks to transform the lives of patients affected by these challenging disorders.

Vedere Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2019. The company focuses on developing gene therapy products aimed at restoring functional vision for patients who have experienced vision loss due to Inherited Retinal Degenerations (IRDs) and other causes of vision impairment, both genetic and non-genetic. Unlike many ocular gene therapies that primarily slow the progression of vision loss, Vedere Bio seeks to restore lost vision, regardless of the patient's genetic background or stage of their condition. As of September 2020, Vedere Bio operates as a subsidiary of Novartis AG.

Dyne Therapeutics is a biotechnology company based in Waltham, Massachusetts, dedicated to developing targeted therapies for genetically driven muscle diseases. Founded in 2017, the company focuses on advancing treatments for conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, among others. Utilizing its innovative FORCE platform, Dyne Therapeutics aims to deliver disease-modifying therapies with enhanced precision to skeletal, cardiac, and smooth muscle tissues. The company's lead product candidates, DYNE-101 and DYNE-251, are currently undergoing phase 1/2 clinical trials, reflecting its commitment to addressing the unmet medical needs of patients with serious muscle disorders.

Triplet Therapeutics, Inc. is focused on developing innovative therapies for repeat expansion disorders, which include conditions such as Huntington’s disease, myotonic dystrophy, and spinocerebellar ataxias. Founded in 2018 and based in Cambridge, Massachusetts, the company aims to address these disorders at their source by utilizing a unique approach that involves targeting the DNA Damage Response pathway through a single oligonucleotide. This biotherapeutic technology is designed to provide a comprehensive treatment solution for multiple repeat expansion disorders, enabling healthcare professionals to better manage these complex conditions.

Remix Therapeutics Inc. is a biotechnology company focused on the research and development of innovative small-molecule therapies that target RNA processing to address various diseases. Established in 2018 and based in Cambridge, Massachusetts, the company employs its proprietary biology platform to identify and prioritize therapeutic targets within RNA processing. Through its REMseq platform, Remix Therapeutics validates potential drug targets and optimizes chemical compounds for therapeutic use. The company's approach aims to reprogram RNA processing to control gene expression, thereby correcting, enhancing, or eliminating problematic gene messages. This enables healthcare providers to tackle the underlying causes of diseases, offering novel solutions to previously undruggable conditions.

Third Harmonic Bio is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for severe allergies and inflammation. The company is focused on creating first-in-class oral small-molecule inhibitors targeting the KIT receptor, which plays a crucial role in the survival and function of mast cells—key immune cells involved in allergic responses. Its lead product candidate, THB001, is designed to provide selective inhibition of KIT, while another candidate, THB335, aims to address multiple mast cell-driven inflammatory diseases affecting the skin, respiratory system, and gastrointestinal tract. Through its research and development efforts, Third Harmonic Bio seeks to advance the management of inflammatory diseases, enhancing patient outcomes and quality of life.

Akero Therapeutics is a clinical-stage biotechnology company based in South San Francisco, California, that specializes in developing treatments for serious metabolic diseases, particularly nonalcoholic steatohepatitis (NASH). Founded in 2017 and formerly known as Pippin Pharmaceuticals, the company is dedicated to addressing the significant unmet medical needs associated with NASH, a condition characterized by liver inflammation and damage, which can lead to severe complications such as fibrosis and liver failure. Akero's lead product candidate, AKR-001, is a long-acting Fc fusion modified FGF21 protein designed to restore metabolic balance by targeting both liver and adipose tissues, thereby reducing liver fat and suppressing inflammation and fibrosis. This innovative approach builds upon two decades of research into FGF21 biology, positioning Akero as a frontrunner in the quest for effective NASH therapies.

Cadent Therapeutics, Inc. is a precision neuroscience company focused on developing innovative therapies for serious neurological and psychiatric disorders. Founded in 2010 and based in Cambridge, Massachusetts, the company specializes in small molecule therapeutics that target NMDA receptors to address conditions such as depression, schizophrenia, Rett syndrome, and other cognitive and movement disorders. Cadent's approach combines target specificity, patient selection, and drug design to create allosteric modulators that can enhance neuronal firing regularity and restore brain rhythms. By leveraging novel quantitative endpoints, Cadent aims to develop first-in-class medications that improve cognitive and motor functions in patients, ultimately enhancing clinical outcomes for those suffering from various neurological diseases.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies that leverage its proprietary technology to maximize the effectiveness of existing immuno-oncology treatments while minimizing side effects outside the tumor. Its lead product, XTX201, is designed to induce immune activity specifically within tumors, demonstrating improved antitumor efficacy. Xilio Therapeutics aims to deliver significant improvements in patient outcomes by utilizing its platform to create a pipeline of novel therapies, including tumor-activated cytokines, antibodies, and immune cell engagers, all targeted to optimize therapeutic effects within the tumor microenvironment. Founded in 2015 and based in Waltham, Massachusetts, the company was previously known as Akrevia Therapeutics before rebranding in March 2020.

Bicycle Therapeutics is a clinical-stage biopharmaceutical company focused on developing a novel class of medicines known as Bicycles, which are synthetic short peptides designed to stabilize their structural geometry through two loops. The company primarily targets oncology indications with significant unmet medical needs. Its lead product candidate, BT1718, is a Bicycle Toxin Conjugate currently undergoing Phase I/IIa clinical trials aimed at tumors expressing Membrane Type 1 matrix metalloprotease. Other oncology candidates include BT5528, also in Phase I/IIa trials targeting EphA2, and BT8009, which is in preclinical studies for Nectin-4. Additionally, Bicycle Therapeutics is developing THR-149, a plasma kallikrein inhibitor that has completed Phase I trials for diabetic macular edema. The company collaborates with various biopharmaceutical organizations to advance programs in areas like anti-infectives and cardiovascular health. Founded in 2009, Bicycle Therapeutics is headquartered in Cambridge, United Kingdom.

HotSpot Therapeutics is a biotechnology startup based in Boston, Massachusetts, established in 2017. The company specializes in the development of allosteric therapies that target regulatory sites on proteins. Its innovative therapeutic platform is designed to identify hotspots and locate pathway treatments for cancer, metabolic disorders, and rare diseases. By leveraging a comprehensive database of hotspot structures and utilizing data science, HotSpot Therapeutics employs a multidisciplinary approach to drug discovery. This approach aims to enhance the effectiveness of treatments and improve patient outcomes across a range of conditions.

Akero Therapeutics is a clinical-stage biotechnology company based in South San Francisco, California, that specializes in developing treatments for serious metabolic diseases, particularly nonalcoholic steatohepatitis (NASH). Founded in 2017 and formerly known as Pippin Pharmaceuticals, the company is dedicated to addressing the significant unmet medical needs associated with NASH, a condition characterized by liver inflammation and damage, which can lead to severe complications such as fibrosis and liver failure. Akero's lead product candidate, AKR-001, is a long-acting Fc fusion modified FGF21 protein designed to restore metabolic balance by targeting both liver and adipose tissues, thereby reducing liver fat and suppressing inflammation and fibrosis. This innovative approach builds upon two decades of research into FGF21 biology, positioning Akero as a frontrunner in the quest for effective NASH therapies.

Nimbus Therapeutics, based in Cambridge, Massachusetts, is a biotechnology company focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. The company utilizes advanced computational technologies to create selective and potent small-molecule therapeutics. Among its notable projects is the Nimbus Apollo program, which features the lead candidate NDI-010976, an allosteric inhibitor targeting Acetyl-CoA Carboxylase (ACC). This compound is being developed for the treatment of non-alcoholic steatohepatitis (NASH) and has potential applications in hepatocellular carcinoma (HCC) and other diseases. NDI-010976 received Fast Track designation from the U.S. Food and Drug Administration in 2016, highlighting its significance in the clinical development pipeline. Nimbus Therapeutics has formed strategic partnerships to enhance its research and development capabilities, reinforcing its commitment to advancing treatment options for complex health challenges.

Accent Therapeutics, Inc. is a biopharmaceutical company based in Lexington, Massachusetts, focused on developing small molecule therapies for oncology through the innovative field of epitranscriptomics. Founded in 2017, the company explores post-transcriptional chemical modifications of RNA, which play a crucial role in regulating proteins essential for cellular growth and differentiation. By precisely targeting RNA-modifying proteins associated with cancer, Accent Therapeutics aims to translate advanced scientific research into effective treatments for patients, ultimately providing new therapeutic options in the fight against cancer.

Plastiq Inc. is a payment service provider that allows users to make payments with credit and debit cards, regardless of whether the recipient accepts card payments. Founded in 2012 and based in San Francisco, California, Plastiq facilitates transactions for various expenses, including tuition, taxes, rent, utilities, and insurance, targeting businesses, institutions, and individual consumers in the United States and Canada. The platform enables users to earn credit card rewards, access early-payment discounts, and manage their cash flow more effectively. By automating B2B payments, Plastiq offers small and medium-sized enterprises a comprehensive suite of services that simplifies the payment process, allowing them to pay or receive payments via credit cards without incurring additional fees. The company aims to provide innovative payment solutions on a global scale, serving customers in over 150 countries.

Avrobio is a clinical-stage gene therapy company based in Cambridge, Massachusetts, focused on developing ex vivo lentiviral gene therapies aimed at treating rare diseases with a single-dose approach. The company utilizes hematopoietic stem cells collected from patients, which are modified using a lentiviral vector to insert functional copies of defective genes associated with specific diseases. Avrobio's lead product candidate, AVR-RD-01, is currently in Phase II clinical trials for Fabry disease. Additionally, the company's pipeline includes AVR-RD-02, which has completed preclinical trials for type 1 Gaucher disease; AVR-RD-03, in preclinical development for Pompe disease; and AVR-RD-04, which has also completed preclinical studies for cystinosis. Avrobio has established a research collaboration with Magenta Therapeutics to explore targeted antibody-drug conjugates as a conditioning regimen for its lentiviral gene therapies. Founded in 2015, Avrobio aims to leverage advancements in cell and gene therapies to provide potential cures for serious and debilitating conditions.

Harbour BioMed is a biotechnology company focused on discovering and developing therapeutics for cancer and inflammatory diseases. Established in 2016 with operations in Shanghai, Cambridge, and Rotterdam, the company leverages its proprietary transgenic mouse platforms to generate fully human monoclonal antibodies (H2L2) and heavy chain only antibodies (HCAb), enabling the development of differentiated compounds such as bi-specific and multi-specific antibodies. Harbour BioMed collaborates strategically with various institutions and companies, including The Wistar Institute, WuXi Biologics, and Vir Biotechnology, to advance its pipeline of therapeutics targeting autoimmune diseases, dry eye disease, COVID-19, and other indications.

Generation Bio is a genetic medicines company based in Cambridge, Massachusetts, that specializes in developing innovative gene therapies for both rare and prevalent diseases. Founded in 2016 and originally named Torus Therapeutics, the company focuses on treating conditions primarily affecting the liver and retina, as well as diseases of skeletal muscle, the central nervous system, and oncology. Generation Bio employs a proprietary non-viral platform that includes a high-capacity DNA construct known as closed-ended DNA (ceDNA) and a cell-targeted lipid nanoparticle delivery system (ctLNP). This platform aims to deliver genetic payloads effectively across various tissues and allows for redosable treatments tailored to individual patient needs. Through its advanced manufacturing processes, Generation Bio seeks to expand access to gene therapies and provide durable solutions for patients with both rare and common diseases.

Quench Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing therapies for inflammatory diseases through the exploration of gasdermin biology and innate immunity. The company’s lead compounds specifically target and inhibit Gasdermin D, a protein involved in the processes of pyroptosis and NETosis, which play a crucial role in the release of inflammatory cytokines, alarmins, DNA, and neutrophil extracellular traps (NETs). By addressing these pathways, Quench Bio aims to provide relief for patients suffering from severe inflammatory conditions. Originally founded as Project Pyro, the company changed its name to Quench Bio in June 2018.

Korro Bio Inc., established in 2018 and headquartered in Cambridge, Massachusetts, specializes in developing nucleic acid-based therapeutics targeting specific sequences in genetic code to treat rare diseases. The company's proprietary platform enables efficient and selective RNA editing, leveraging natural processes common to all multicellular organisms. Korro Bio aims to advance this technology to effect changes in protein structure and function across multiple tissues, expanding the reach of genetic medicines with additional precision and tunability by editing RNA instead of DNA.

Ikena Oncology, Inc. is a biotechnology company focused on discovering and developing biomarker-driven therapies for cancer treatment. It specializes in precision oncology by targeting pathways essential for cancer growth and therapeutic resistance, particularly within the Hippo and RAS signaling networks. The company's portfolio includes several preclinical and discovery-stage programs, such as IK-007, an EP4 receptor antagonist; IK-175, an AHR antagonist; and IK-412, a kynurenine-degrading enzyme. Additionally, Ikena is developing IK-930, an oral small-molecule inhibitor of the TEAD transcription factor involved in the Hippo pathway. Ikena Oncology, originally founded as Kyn Therapeutics in 2016, rebranded in December 2019 and is headquartered in Boston, Massachusetts. The company aims to address significant medical needs in oncology through innovative drug development.

Obsidian Therapeutics develops innovative cell and gene therapies aimed at enhancing adoptive immunotherapy for cancer patients. Founded in 2015 and based in Cambridge, Massachusetts, the company focuses on creating next-generation therapies that utilize pharmacologic operating systems to provide precise control over protein activity within cells. This technology allows for the development of adoptive cell therapies with advanced functionalities that can be managed by physicians using simple, safe, and orally active medications. By offering improved control over treatment, Obsidian Therapeutics aims to provide better outcomes for patients compared to existing cell therapy options.

Kymera Therapeutics is a biopharmaceutical company based in Watertown, Massachusetts, that specializes in the discovery and development of novel small molecule therapeutics aimed at selectively degrading disease-causing proteins. The company utilizes a proprietary platform for targeted protein degradation, leveraging the body’s natural protein recycling system. Kymera is developing several programs, including the IRAK4 program for immunology-inflammation diseases such as hidradenitis suppurativa and rheumatoid arthritis, the IRAKIMiD program to address MYD88-mutated diffuse large B cell lymphoma, and the STAT3 program targeting hematologic malignancies, solid tumors, and autoimmune diseases. Founded in 2015, Kymera Therapeutics is pioneering new approaches to treat diseases that have previously been considered untreatable, focusing on previously inaccessible therapeutic targets.

Gemini Therapeutics, Inc. is a precision medicine company based in Cambridge, Massachusetts, founded in 2015. The company specializes in developing new therapies for patients experiencing dry age-related macular degeneration (AMD) and related rare genetic diseases. Gemini Therapeutics focuses on genetically defined conditions, creating therapeutic candidates that address molecular abnormalities in patients with significant clinical needs. Their diverse pipeline encompasses monoclonal antibodies, recombinant proteins, and gene therapies, positioning the company to potentially introduce first-in-class therapeutics. The development of these innovative treatment options is supported by collaborations with leading life science investors and academic institutions worldwide, reflecting a commitment to advancing medical care for individuals suffering from these conditions.

Disarm Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for patients suffering from neurological diseases. Founded in 2016 and headquartered in Cambridge, Massachusetts, the company aims to create disease-modifying drugs that prevent axonal degeneration, which is a key factor in various neurological disorders. Disarm's portfolio addresses conditions such as multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies, providing potential treatments for acute diseases affecting the central, ocular, and peripheral nervous systems. As of late 2020, Disarm Therapeutics operates as a subsidiary of Eli Lilly and Company.

Rodin Therapeutics is a biotechnology company based in Cambridge, Massachusetts, focused on developing therapeutics for cognitive disorders through the application of epigenetic insights. Founded in 2013 with backing from Atlas Venture and Johnson & Johnson Development Corporation, the company leverages advanced structural biology capabilities and a team experienced in central nervous system (CNS) drug development. Rodin's innovative approach centers on the modulation of histone deacetylase (HDAC) complexes to restore synaptic function and promote neuronal health in degenerative brain diseases. This strategy aims to address significant unmet medical needs in the treatment of neurological disorders. As of November 2019, Rodin operates as a subsidiary of Alkermes Inc.

Replimune Group, Inc., established in 2015 and based in Woburn, Massachusetts, is a biotechnology company specializing in the development of oncolytic immune-gene therapies for cancer treatment. The company's proprietary Immulytic platform enables the design of product candidates that directly attack cancer cells and stimulate the immune system. Replimune's lead candidate, RP1, is a modified herpes simplex virus currently in Phase I/II trials for various solid tumors and Phase II trials for cutaneous squamous cell carcinoma. Additionally, RP2 and RP3 are in early-stage clinical trials, targeting immune checkpoint inhibition and T-cell stimulation, respectively. Replimune aims to rapidly advance these therapies through clinical trials and explore combinations with other immuno-oncology products.

Indalo Therapeutics is a preclinical-stage biotechnology company focused on developing innovative therapies for patients afflicted by fibrotic diseases. Founded on significant scientific advancements, the company leverages deep insights into the molecular mechanisms that drive abnormal scarring. By assembling a skilled team of pharmaceutical scientists and industry executives, Indalo aims to address critical unmet medical needs in the field of fibrosis. Its therapeutic approach seeks to not only halt but also potentially reverse the progression of fibrotic conditions, ultimately improving the quality of life for affected individuals.

Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is currently undergoing Phase I/IIa clinical trials for the treatment of phenylketonuria, a rare genetic metabolic disorder. Additionally, Synlogic is advancing SYNB1891, an intratumoral synthetic biotic medicine in Phase I clinical trials targeting solid tumors and lymphoma. The company employs a proprietary approach that utilizes engineered probiotics, specifically Escherichia coli Nissle 1917, to create GI-restricted oral therapies that are non-colonizing and reversible, facilitating easier administration and storage. Synlogic is also exploring treatments for other conditions, including secondary hyperoxaluria, inflammatory bowel disease, and various metabolic disorders, and has established a collaboration with Ginkgo Bioworks to further its development efforts.

Magenta Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies to enhance stem cell transplantation for patients with blood cancers, genetic diseases, and autoimmune disorders. The company aims to improve the safety and efficacy of stem cell transplants, which are currently high-risk procedures often considered only as a last resort. Its pipeline includes several key product candidates, such as targeted antibody-drug conjugates for transplant conditioning, a novel stem cell mobilization agent, and allogeneic stem cell therapies. Magenta is also exploring collaborations to assess the effectiveness of its therapies in combination with existing treatments, such as gene therapies for sickle cell disease. Founded in 2015 and headquartered in Cambridge, Massachusetts, Magenta Therapeutics seeks to expand the curative potential of stem cell therapies to a broader patient population by addressing the toxicity and long-term side effects associated with current transplant methods.

SimpleReach, Inc. provides a platform that tracks social interaction with published content to deliver insights and performance metrics related to social behavior. By integrating data from various channels and websites, the company offers a comprehensive view of content effectiveness, helping clients enhance their return on content investments. Utilizing advanced machine learning and artificial intelligence, SimpleReach assists marketers in refining future campaigns and enables publishers to create dashboards for monitoring and reporting on campaign performance. The company serves a range of clients, including notable brands like Intel, Chase, and Home Depot, who rely on its platform to gain actionable insights and improve content impact. Founded in 2010 and based in New York, SimpleReach operates as a subsidiary of Nativo, Inc. since March 2019.